Gene therapy delivering a paraoxonase 1 variant offers long-term prophylactic protection against nerve agents in mice

Chemical warfare nerve agents are organophosphorus chemical compounds that induce cholinergic crisis, leaving little or no time for medical intervention to prevent death. The current chemical treatment regimen may prevent death but does not prevent postexposure complications such as brain damage and...

Full description

Saved in:

Bibliographic Details
Published in:	Science translational medicine Vol. 12; no. 527
Main Authors:	Betapudi, Venkaiah, Goswami, Reena, Silayeva, Liliya, Doctor, Deborah M, Chilukuri, Nageswararao
Format:	Journal Article
Language:	English
Published:	United States 22-01-2020
Subjects:	Animals Aryldialkylphosphatase - genetics Aryldialkylphosphatase - metabolism Genetic Therapy - methods Humans Mice Nerve Agents - adverse effects
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Chemical warfare nerve agents are organophosphorus chemical compounds that induce cholinergic crisis, leaving little or no time for medical intervention to prevent death. The current chemical treatment regimen may prevent death but does not prevent postexposure complications such as brain damage and permanent behavioral abnormalities. In the present study, we have demonstrated an adeno-associated virus 8 (AAV8)-mediated paraoxonase 1 variant IF-11 (PON1-IF11) gene therapy that offers asymptomatic prophylactic protection to mice against multiple lethal doses of G-type chemical warfare nerve agents, namely, tabun, sarin, cyclosarin, and soman, for up to 5 months in mice. A single injection of liver-specific adeno-associated viral particles loaded with PON1-IF11 gene resulted in expression and secretion of recombinant PON1-IF11 in milligram quantities, which has the catalytic power to break down G-type chemical warfare nerve agents into biologically inactive products in vitro and in vivo in rodents. Mice containing milligram concentrations of recombinant PON1-IF11 in their blood displayed no clinical signs of toxicity, as judged by their hematological parameters and serum chemistry profiles. Our study unfolds avenues to develop a one-time application of gene therapy to express a near-natural and circulating therapeutic PON1-IF11 protein that can potentially protect humans against G-type chemical warfare nerve agents for several weeks to months.
ISSN:	1946-6242
DOI:	10.1126/scitranslmed.aay0356